A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia

American Journal of Cardiology

Volumn 80, Issue 1, 1997, Pages 39-44

  Dart, Anthony ^b   Jerums, George ^b   Nicholson, Geoffrey ^b   D'Emden, Michael ^b   Hamilton Craig, Ian ^b   Tallis, George ^b   Best, James ^b   West, Malcolm ^b   Sullivan, David ^b   Bracs, Peter ^b   Black, Donald ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTHRALGIA; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; ARTHRALGIA; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERLIPIDEMIAS; LOVASTATIN; MALE; MIDDLE AGED; PATIENT EDUCATION; PYRROLES; SIMVASTATIN; TRIGLYCERIDES;

EID: 0031195278     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00280-4     Document Type: Article

References (19)

1. 1. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;82:1916-1924.
2. 2. Lovastatin Study Groups I through IV. Lovastatin 5-year Safety and Efficacy Study. Arch Intern Med 1993;153:1079-1087.
3. 3. Farnier JA, Washington LC, Jones PH, Shapiro DR, Gotto AM, Mantell G. Comparative Effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Therap 1992;14:708-717.
4. 4. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
5. 5. Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis; in press.
6. 6. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black DM. for the atorvastatin study group. Comparison of one-year efficacy and safety of atorvastatin-versus-lovastaun in primary hypercholesterolemia. Am J Cardiol; 79:in press.
7. 7. Bakker-Arkema R, Davidson M, Goldstein R, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
8. 8. Best JD, Nicholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Kin-Wah C, Sanders KM. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr and Metab 1996;9:74-80.
9. 9. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a new HMG-CoA reductase inhibitor as mono-therapy and combined with Colestipol. J Cardiovasc Pharmacol Ther 1996;2:117-122.
10. 10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
11. 11. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. 12. Lipids Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA 1984;251:351-364.
13. 13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
14. 14. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL;, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, Cole TG, Braunwald E, for the CARE Investigators. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995;76:98C-106C.
15. 15. Schaefer EJ, Genest JJ Jr, Ordovas JM, Salem DN, Wilson PW. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis 1994;108(suppl):S41-S54.
16. 16. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.
17. 17. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1991;13:427-434.
18. 18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;20:1301-1307.
19. 19. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J. Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluations of lovastatin (EXCEL) study results 1. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.